{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-041187","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.002642+00:00","generated_at":"2026-05-24T13:39:40.085666+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Trevi Therapeutics Reports Q4 and Full Year 2024 Financial Results and Provides Positive Clinical Updates","bullets":["Announced positive topline data from Phase 2a RIVER trial in refractory chronic cough, meeting primary endpoint with 57% placebo-adjusted reduction in 24-hour cough frequency.","Completed enrollment in Phase 2b CORAL trial in IPF patients with chronic cough, topline data expected Q2 2025.","Sample size re-estimation for CORAL trial reaffirmed original sample size of 160 patients.","Ended 2024 with $107.6 million cash, expected runway into H2 2026.","Net loss for 2024 was $47.9 million, compared to $29.1 million in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-041187","json":"https://secwatch.observer/filing/0000950170-25-041187.json","markdown":"https://secwatch.observer/filing/0000950170-25-041187.md","text":"https://secwatch.observer/filing/0000950170-25-041187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025041187/0000950170-25-041187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025041187/trvi-20250318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-24T13:39:40.085666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}